<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
AMENDMENT NO. 2
TO
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
ALEXION PHARMACEUTICALS, INC.
- --------------------------------------------------------------------------------
(Name of Issuer)
COMMON STOCK, $.0001 PAR VALUE
- --------------------------------------------------------------------------------
(Title of Class of Securities)
015351109
(CUSIP Number)
Mark H. Swartz
Executive Vice President
c/o Tyco International (US) Inc.
One Tyco Park
Exeter, NH 03833
(603) 778-9700
Michael W. Lyons
Corporate Counsel
United States Surgical Corporation
150 Glover Avenue
Norwalk, Connecticut 06856
(203) 845-1000
with a copy to:
Frederick W. Kanner, Esq.
Dewey Ballantine LLP
1301 Avenue of the Americas
New York, New York 10019-6092
(212) 259-8000
- --------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
OCTOBER 1, 1998
- --------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check
the following box |_|.
NOTE: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See Rule 13d-7 for other parties
to whom copies are to be sent.
(Continued on following pages)
(Page 1 of 9 Pages)
<PAGE>
SCHEDULE 13D
- --------------------------------------------------------------------------------
CUSIP NO. 015351109 PAGE 2 OF 9 PAGES
------------------------------
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON: Tyco International Ltd.
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON:
Not Applicable
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) /X/
(b) / /
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
AF
- --------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) /_/
- --------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Bermuda
- --------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF SHARES
BENEFICIALLY Not Applicable
OWNED BY --------------------------------------------------
EACH 8 SHARED VOTING POWER
REPORTING
PERSON 824,087 (See Item 5)
WITH --------------------------------------------------
9 SOLE DISPOSITIVE POWER
Not Applicable
--------------------------------------------------
10 SHARED DISPOSITIVE POWER
824,087 (See Item 5)
- --------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
824,087
- --------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11)
EXCLUDES CERTAIN SHARES* /_/
Not Applicable
- --------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
7.3%
- --------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION
<PAGE>
SCHEDULE 13D
- --------------------------------------------------------------------------------
CUSIP NO. 015351109 PAGE 3 OF 9 PAGES
------------------------------
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON: United States Surgical Corporation
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON:
132518270
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) /X/
(b) / /
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
AF/WC
- --------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) /_/
- --------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- --------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF SHARES
BENEFICIALLY Not Applicable
OWNED BY --------------------------------------------------
EACH 8 SHARED VOTING POWER
REPORTING
PERSON 824,087 (See Item 5)
WITH --------------------------------------------------
9 SOLE DISPOSITIVE POWER
Not Applicable
--------------------------------------------------
10 SHARED DISPOSITIVE POWER
824,087 (See Item 5)
- --------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
824,087
- --------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11)
EXCLUDES CERTAIN SHARES* /_/
Not Applicable
- --------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
7.3%
- --------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION
<PAGE>
Tyco International Ltd., a Bermuda company ("Tyco") and United States
Surgical Corporation, a Delaware corporation and an indirect wholly owned
subsidiary of Tyco ("US Surgical") hereby further amend and supplement Statement
on 13D previously filed by US Surgical (the "Schedule 13D") relating to the
common stock $.0001 par value (the "Common Stock"), of Alexion Pharmaceuticals,
Inc., a Delaware corporation (the "Issuer"), originally filed with the
Securities and Exchange Commission (the "Commission") on February 29, 1996, as
amended. The item numbers and responses thereto below are in accordance with the
requirements of Schedule 13D.
Unless otherwise indicated herein, each capitalized term used but not
defined herein shall have the meaning assigned to such term in the Schedule 13D.
The term Reporting Persons means Tyco and US Surgical.
ITEM 2. IDENTITY AND BACKGROUND.
Item 2 is hereby amended and supplemented by adding the following
information with respect to Tyco as follows:
(a) - (c) Tyco's registered offices are located at The Gibbons
Building, 10 Queen Street, Hamilton HM11 Bermuda, and its telephone number is
(441) 292-8674. The executive offices of Tyco International (US) Inc., Tyco's
principal United States subsidiary, are located at One Tyco Park, Exeter, New
Hampshire 03833, and its telephone number is (603) 778-9700.
Tyco is a diversified manufacturing and service company that, through
its subsidiaries, operates in four segments: (i) the manufacture and
distribution of disposable medical supplies and other specialty products, and
the conduct of vehicle auctions and related services; (ii) the design,
manufacture, installation and service of fire detection and suppression systems,
and the installation, monitoring and maintenance of electronic security systems;
(iii) the design, manufacture and distribution of flow control products; and
(iv) the design, manufacture and distribution of electrical and electronic
components, and the design, manufacture, installation and service of undersea
cable communication systems.
The name, business address and present principal occupation or
employment of each of the executive officers and directors of Tyco, are set
forth on Schedule II annexed hereto, which is incorporated herein by reference.
(d) - (e) During the last five years, none of Tyco, and, to the best
knowledge of Tyco, none of the persons listed on Schedule II hereto, has been
convicted in a criminal proceeding (excluding traffic violations and similar
misdemeanors) or has been a party to a civil proceeding of a judicial or
administrative body of competent jurisdiction and as a result of such proceeding
was or is subject to a judgment, decree or final order enjoining future
violations of, or prohibiting or mandating activities subject to, Federal or
state securities laws or finding any violation with respect to such laws.
(f) Except as indicated on Schedule II each natural person identified
in this amendment to Item 2 is a citizen of the United States.
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.
Item 3 is hereby amended and supplemented by adding the following
information with respect to Tyco as follows:
Tyco acquired its beneficial ownership in the Common Stock of the
Issuer as a
(Page 4 of 9 Pages)
<PAGE>
result of the consummation, on October 1, 1998, of the merger (the "Tyco/US
Surgical Merger") of US Surgical with a subsidiary of Tyco. In the merger, each
share of common stock of US Surgical was exchanged for 0.7606 common shares of
Tyco.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.
(a) Number of Shares Beneficially Owned:
As October 1, 1998, the Reporting Persons owned an
aggregate of 824,087 shares of Common Stock of the
Issuer. Based upon publicly available information,
such shares represented 7.3% of the outstanding
shares(1).
(b) Sole or shared Power to Vote, Direct the Vote of,
Dispose of, or Direct the Disposition of Shares:
The Reporting Persons share the power to vote or to
direct the vote, and share the power to dispose or to
direct the disposition, of the Shares held by them.
(c) Recent Transactions:
Other than the indirect acquisition of the shares of
Common Stock by Tyco as a result of the Tyco/US
Surgical Merger, none of the Reporting Persons, as of
October 1, 1998, had effected any transaction in the
class of securities reported.
(d) Rights with Respect to Dividends on Sales Proceeds:
Not Applicable.
(e) Date of Cessation of Five Percent Beneficial
Ownership:
Not Applicable.
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.
Item 7 of the Schedule 13D is hereby amended and supplemented
by the following:
<TABLE>
<CAPTION>
EXHIBIT NO. DESCRIPTION
- ----------- -----------
<S> <C>
1 Agreement of Joint Filing pursuant to Rule
13d-1(k)(1) promulgated under the
Securities Exchange Act of 1934, as
amended.
</TABLE>
- ------------------------------
(1) As of May 29, 1998, 11,225,112 Shares were outstanding.
(Page 5 of 9 Pages)
<PAGE>
SCHEDULE II
EXECUTIVE OFFICERS AND DIRECTORS
The name and present principal occupation or employment of each of the executive
officers and directors of Tyco International Ltd. ("Tyco") are set forth below.
<TABLE>
<CAPTION>
NAME AND POSITION HELD CURRENT BUSINESS ADDRESS PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT
---------------------- ------------------------ ------------------------------------------
<S> <C> <C>
L. Dennis Kozlowski c/o Tyco International (US) Chairman of the Board, President and Chief
Chairman of the Board, Inc. ("Tyco (US)") Executive Officer of Tyco
President & Chief Executive One Tyco Park
Officer Exeter, NH 03833
Michael A. Ashcroft P.O. Box 1598 Non-executive Chairman of BHI Corporation
Director (citizen of Belize) Belize City, Belize
Joshua M. Berman 919 Third Avenue Counsel to the law firm of Kramer, Levin,
Director and Vice President New York, NY 10022 Naftalis & Frankel
Richard S. Bodman 2 Wisconsin Circle Managing General Partner of AT&T Ventures LLC
Director Suite 610
Chevy Chase, MD 20815
John F. Fort, III 2003 Milford Street Director of Tyco
Director Houston, TX 77098
Steven W. Foss 380 Lafayette Rd. President of Foss Manufacturing Company, Inc.
Director Hampton, NH 03842
Richard A. Gilleland 2829 Townsgate Rd. President of Tyco Healthcare Products Group
Director Suite 101
West Lake Village, CA 91361
Phillip M. Hampton 152 West 57th Street Co-Managing Director of R.H. Arnold & Co.
Director 44th Floor
New York, NY 10019
James S. Pasman, Jr. 29 The Trillium Director of Tyco
Director Pittsburgh, PA 15238
W. Peter Slusser One Citicorp Center President of Slusser Associates, Inc.
Director Suite 5100
153 East 53rd Street
New York, NY 10022
Frank E. Walsh, Jr. 330 South Street Chairman of Sandyhill Foundation
Director Morristown, NJ 07962-1975
Jerry R. Boggess c/o Tyco (US) Vice President of Tyco (US)
Vice President of Tyco (US) Three Tyco Park
Exeter, NH 03833
</TABLE>
(Page 6 of 9 Pages)
<PAGE>
<TABLE>
<CAPTION>
NAME AND POSITION HELD CURRENT BUSINESS ADDRESS PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT
---------------------- ------------------------ ------------------------------------------
<S> <C> <C>
David P. Brownell c/o Tyco (US) Senior Vice President of Tyco (US)
Senior Vice President 1750 Clintmore Rd.
P.O. Box 5034
Boca Raton, FL 33431
Robert P. Mead c/o Tyco (US) Vice President of Tyco (US)
Vice President of Tyco (US) Three Tyco Park
Exeter, NH 03833
Richard J. Meelia 15 Hampshire Street Vice President of Tyco (US)
Vice President of Tyco (US) Mansfield, MA 02048
Mark H. Swartz c/o Tyco (US) Executive Vice President & Chief Financial
Executive Vice President & One Tyco Park Officer of Tyco
Chief Financial Officer Exeter, NH 03833
Mark A. Belnick c/o Tyco (US) Executive Vice President & Chief Corporate
Executive Vice President & 712 Fifth Avenue - 48th Floor Counsel of Tyco
Chief Corporate Counsel New York, NY 10019
</TABLE>
(Page 7 of 9 Pages)
<PAGE>
After reasonable inquiry and to the best knowledge and belief of the
undersigned, the undersigned certifies that the information set forth in this
statement is true, complete and correct.
Date: January 21, 1999
TYCO INTERNATIONAL LTD.
By: /s/ Mark H. Swartz
----------------------------------------
Name: Mark H. Swartz
Title: Executive Vice President, Chief
Financial Officer
UNITED STATES SURGICAL CORPORATION
By: /s/ Mark H. Swartz
----------------------------------------
Name: Mark H. Swartz
Title:Vice President
(Page 8 of 9 Pages)
<PAGE>
Exhibit 1
Agreement of Joint Filing
Pursuant to 13d-1(k)(1) promulgated under the Securities Exchange Act
of 1934, as amended, the undersigned persons hereby agree to file with the
Securities and Exchange Commission the Statement on Schedule 13D (the
"Statement") to which this Agreement is attached as an exhibit, and agree that
such Statement, as so filed, is filed on behalf of each of them.
IN WITNESS WHEREOF, the undersigned have executed this Agreement.
TYCO INTERNATIONAL LTD.
By: /s/ Mark H. Swartz
----------------------------------------
Name: Mark H. Swartz
Title: Executive Vice President, Chief
Financial Officer
UNITED STATES SURGICAL CORPORATION
By: /S/ Mark H. Swartz
----------------------------------------
Name: Mark H. Swartz
Title:Vice President
(Page 9 of 9 Pages)
